Patents by Inventor Dale B. Schenk

Dale B. Schenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention and treatment of amyloidogenic disease
    Patent number: 8034348
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: October 11, 2011
    Assignee: Janssen Alzheimer Immunotherapy
    Inventors: Dale B. Schenk, Nicki Vasquez, Theodore Yednock
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20110224408
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 15, 2011
    Applicants: ELAN PHARMACEUTICALS, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José W. Saldanha
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20110218328
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 8, 2011
    Applicants: Elan Pharmaceuticals, Inc., University of Tennessee Research Foundation
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José W. Saldanha
  • Methods for determining whether a compound alters the amount of at least one ?? (X-41) peptide and the amount of either total ?? or at least one ?? (X-40) peptide produced by a non-human mammal
    Patent number: 7993627
    Abstract: This invention provides methods of screening compounds for their ability to alter the production of A?(x?41) alone or in combination with A?(x?40). The methods involve administering compounds to cells, specifically measuring the amounts of A?(x?40) and A?(x?41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: August 9, 2011
    Assignees: Elan Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Martin Citron, Dennis J. Selkoe, Peter A. Seubert, Dale B. Schenk
  • PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
    Publication number: 20110182893
    Abstract: Passive immunotherapy methods for treating a patient having atherosclerosis.
    Type: Application
    Filed: February 23, 2011
    Publication date: July 28, 2011
    Inventor: Dale B. SCHENK
  • PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
    Publication number: 20110177066
    Abstract: Passive immunotherapy methods for treating a patient having AL amyloidosis characterized by the presence of amyloid light chain-type protein fibrils.
    Type: Application
    Filed: February 23, 2011
    Publication date: July 21, 2011
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED
    Inventor: Dale B. SCHENK
  • Prevention and treatment of amyloidogenic diseases
    Patent number: 7977316
    Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 12, 2011
    Assignee: Elan Pharmaceuticals, Inc.
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidgenic disease
    Patent number: 7964192
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: June 21, 2011
    Assignee: Janssen Alzheimer Immunotherapy
    Inventor: Dale B. Schenk
  • PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE
    Publication number: 20110135660
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: March 23, 2010
    Publication date: June 9, 2011
    Applicants: JANSSEN ALZHEIMER IMMUNOTHERAPY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dale B. Schenk, Eliezer Masliah
  • Chimeric, humanized, or human antibody 2A4
    Patent number: 7928203
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: April 19, 2011
    Assignees: Elan Pharmaceuticals, Inc., University of Tennessee Research Foundation
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, José W. Saldanha
  • Treatment and delay of onset of synucleinopathic and amyloidogenic disease
    Patent number: 7919088
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 5, 2011
    Assignees: Elan Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah
  • PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
    Publication number: 20110064734
    Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
    Type: Application
    Filed: November 5, 2010
    Publication date: March 17, 2011
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventor: DALE B. SCHENK
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7893214
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: February 22, 2011
    Assignee: Janssen Alzheimer Immunotherapy
    Inventor: Dale B. Schenk
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20110038790
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: December 29, 2008
    Publication date: February 17, 2011
    Inventors: Dale B. Schenk, Peter A. Seubert, Johathan Wall, Jose Saldanhe
  • Prevention and treatment of synucleinopathic and amyloidogenic disease
    Publication number: 20100278814
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 25, 2008
    Publication date: November 4, 2010
    Applicants: ELAN PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-? peptide (x-?41) and tau
    Patent number: 7811769
    Abstract: This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-? peptide (x??41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A?(x??41) and tau. Low levels of A?(x??41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A?(x??41) and low levels of tau are a negative indication of Alzheimer's disease.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: October 12, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Peter A. Seubert, Carmen Vigo-Pelfrey, Dale B. Schenk, Robin Barbour
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7790856
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: September 7, 2010
    Assignee: Janssen Alzheimer Immunotherapy
    Inventor: Dale B. Schenk
  • Treatment and delay of outset of Parkinson's disease
    Patent number: 7727957
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: June 1, 2010
    Assignees: Janssen Alzheimer Immunotherapy, The Regents Of The University Of California
    Inventors: Dale B. Schenk, Eliezer Masliah
  • Humanized antibodies that recognize ?-amyloid peptide
    Patent number: 7700751
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: April 20, 2010
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
    Publication number: 20100086545
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 22, 2008
    Publication date: April 8, 2010
    Applicants: The Regents of the University of California, Elan Pharmaceuticals, Inc.
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Chilcote J. Tamie, Edward Rockenstein, Kate Dora Games